What happened
The MHRA launched a UK safety campaign in response to illegal advertising and rapid-weight-loss claims involving GLP-1 medicines.
What we know
The regulator advises against speeding up dose escalation or changing doses without direction, and says prescription medicines should come through legal channels. It also highlights nutrition and physical activity during treatment.
Jurisdiction
This notice concerns the UK system. Prescribing, supply and adverse-event reporting routes differ across the US, Canada, Australia, Ireland and other markets.
Why it matters
The campaign addresses preventable behaviours and misleading promotion; it neither compares brands nor recommends treatment. Side effects and concerns should be discussed with the responsible healthcare professional.